Two weeks from now (March 9, 3 PM EST/noon PST), Dr. Lecia Sequist of Massachusetts General Hospital will lead a free online webinar that is a joint program between GRACE and LUNGevity, on the topic of "Acquired Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): What We Know Now, and How We’re Moving Forward", to be followed by an interactive Q&A session.
Dr. Sequist is a medical oncologist and Assistant Professor of Medicine, Harvard Medical School; Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, and she is also one of the people at the forefront of management questions for patients with an activating EGFR mutation.
Some highlight issues we'll plan to cover:
1. What is known about the timing of development of acquired resistance to oral EGFR TKIs?
2. Is there anything known about ways to postpone acquired resistance?
3. Once progression is documented, is there anything to be done to restore/improve activity of these agents?
4. Are there data to speak to concept of continuing an EGFR TKI while adding chemo or some other agent, vs. stopping it at progression and switching to new therapy?
5. What is known about mechanisms of acquired resistance and any differences in clinical behavior and outcomes among these?
6. What practically useful information can be gained from re-biopsy at progression?
7. What are practical barriers to re-biopsy at progression?
8. What clinical trials are available for motivated patients?
Although this topic is most directly relevant to the minority of lung cancer patients with an activating EGFR mutation, the question of how to manage acquired resistance after a good initial response is a timely issue that is becoming increasingly relevant in our increasingly molecularly-defined approach to lung cancer.
For those interested and able to attend the live program, you can register here (registration info to be shared between GRACE and LUNGevity). For those who can't attend the live event or who don't want to worry about taking notes, we'll make this content available as a free podcast (audio or video) for everyone.